JP6884800B2 - メマンチン化合物及びその調整並びにその使用 - Google Patents

メマンチン化合物及びその調整並びにその使用 Download PDF

Info

Publication number
JP6884800B2
JP6884800B2 JP2018558278A JP2018558278A JP6884800B2 JP 6884800 B2 JP6884800 B2 JP 6884800B2 JP 2018558278 A JP2018558278 A JP 2018558278A JP 2018558278 A JP2018558278 A JP 2018558278A JP 6884800 B2 JP6884800 B2 JP 6884800B2
Authority
JP
Japan
Prior art keywords
alkyl
aryl
alkoxy
heteroaryl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018558278A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019521958A5 (enExample
JP2019521958A (ja
Inventor
ヘ、ビフェイ
ファン、ユピン
ル、フイシオン
リウ、グアンユアン
ワン、ゾンキン
ルオ、ゾンフア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Lake Pharma Co Ltd
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of JP2019521958A publication Critical patent/JP2019521958A/ja
Publication of JP2019521958A5 publication Critical patent/JP2019521958A5/ja
Priority to JP2021074004A priority Critical patent/JP2021119163A/ja
Application granted granted Critical
Publication of JP6884800B2 publication Critical patent/JP6884800B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/02—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from isocyanates with formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/04—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2018558278A 2016-05-07 2017-05-05 メマンチン化合物及びその調整並びにその使用 Active JP6884800B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021074004A JP2021119163A (ja) 2016-05-07 2021-04-26 メマンチン化合物及びその調整並びにその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610300245 2016-05-07
CN201610300245.5 2016-05-07
PCT/CN2017/083129 WO2017193870A1 (en) 2016-05-07 2017-05-05 Memantine compounds and their preparation and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021074004A Division JP2021119163A (ja) 2016-05-07 2021-04-26 メマンチン化合物及びその調整並びにその使用

Publications (3)

Publication Number Publication Date
JP2019521958A JP2019521958A (ja) 2019-08-08
JP2019521958A5 JP2019521958A5 (enExample) 2020-05-07
JP6884800B2 true JP6884800B2 (ja) 2021-06-09

Family

ID=60266756

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018558278A Active JP6884800B2 (ja) 2016-05-07 2017-05-05 メマンチン化合物及びその調整並びにその使用
JP2021074004A Pending JP2021119163A (ja) 2016-05-07 2021-04-26 メマンチン化合物及びその調整並びにその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021074004A Pending JP2021119163A (ja) 2016-05-07 2021-04-26 メマンチン化合物及びその調整並びにその使用

Country Status (4)

Country Link
US (2) US10800734B2 (enExample)
JP (2) JP6884800B2 (enExample)
CN (2) CN109152752A (enExample)
WO (1) WO2017193870A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021119163A (ja) * 2016-05-07 2021-08-12 サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co., Ltd. メマンチン化合物及びその調整並びにその使用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109959731B (zh) * 2017-12-26 2022-07-08 广东东阳光药业有限公司 一种用hplc法测定美金刚衍生物的方法
CN110433131B (zh) * 2018-05-03 2024-09-03 广东东阳光药业股份有限公司 一种药物组合物
CN111662216A (zh) * 2019-03-05 2020-09-15 广东东阳光药业有限公司 一种金刚烷胺类化合物的晶型及其制备方法
JP2022553229A (ja) * 2019-10-16 2022-12-22 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 薬物組成物
WO2024012565A1 (zh) * 2022-07-15 2024-01-18 广州市恒诺康医药科技有限公司 美金刚衍生物、其药物组合物及其用途
WO2025011640A1 (zh) * 2023-07-13 2025-01-16 广州市恒诺康医药科技有限公司 美金刚衍生物、其药物组合物及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614560A (en) * 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US6444702B1 (en) * 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
CN100351225C (zh) 2004-10-28 2007-11-28 中国医学科学院医药生物技术研究所 一组金刚烷胺类衍生物及其合成方法和作为神经元损伤保护剂的应用
JP2010026942A (ja) * 2008-07-23 2010-02-04 Hitachi Ltd 情報処理システム
WO2013088255A1 (en) * 2011-12-15 2013-06-20 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
EP2961403A4 (en) 2013-03-01 2016-11-30 Zalicus Pharmaceuticals Ltd HETEROCYCLIC INHIBITORS OF SODIUM CHANNEL
CN103553932B (zh) 2013-11-12 2015-03-25 江苏正大清江制药有限公司 一种适合工业化制备盐酸美金刚的方法
CN108024990B (zh) 2015-08-31 2020-08-11 深圳青雅启瑞生物科技有限公司 美金刚与牛蒡子苷元的缀合物及其组合物和用途
US10800734B2 (en) * 2016-05-07 2020-10-13 Sunshine Lake Pharma Co., Ltd. Memantine compounds and their preparation and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021119163A (ja) * 2016-05-07 2021-08-12 サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co., Ltd. メマンチン化合物及びその調整並びにその使用

Also Published As

Publication number Publication date
JP2019521958A (ja) 2019-08-08
CN113336673A (zh) 2021-09-03
US20190144378A1 (en) 2019-05-16
US20200399208A1 (en) 2020-12-24
US10800734B2 (en) 2020-10-13
CN109152752A (zh) 2019-01-04
JP2021119163A (ja) 2021-08-12
WO2017193870A1 (en) 2017-11-16

Similar Documents

Publication Publication Date Title
JP6884800B2 (ja) メマンチン化合物及びその調整並びにその使用
TWI813666B (zh) 一種多功能化合物、其製備方法及其在醫藥上的應用
AU2017289038B2 (en) Immunomodulator compounds
EP3684772B1 (en) Cyclic iminopyrimidine derivatives as kinase inhibitors
RU2513856C2 (ru) Способы получения метилового эфира 4-оксооктагидроиндол-1-карбоновой кислоты и ее производные
JP2022502510A (ja) ニトロキソリンプロドラッグ及びその使用
JP7477076B2 (ja) グルタルイミド骨格に基づく化合物及びその使用
US20190040054A1 (en) Solid state forms of dasatinib and processes for their preparation
CN114409653A (zh) 一种桥环并嘧啶并环类化合物及其用途
CA3211820A1 (en) Isoquinolone compound and use thereof
JP2005530691A (ja) 新規なチロインジシンとその関連プロセス、薬学的組成物および方法
CN114096533B (zh) 一种三并环类化合物，包含其的药物组合物，其制备方法及其用途
JPWO2013147216A1 (ja) （２−ヘテロアリールアミノ）コハク酸誘導体
CN111902401B (zh) 受体抑制剂、包含其的药物组合物及其用途
JP2018516916A (ja) ガリエララクトンのエーテル類似体
WO2024193464A1 (zh) 一种含氮三并环衍生物及其在医药上的应用
JP2025507308A (ja) 化学療法剤および組織結合小分子のコンジュゲート、組成物、ならびにその方法
US20240083844A1 (en) Kinase inhibitors and uses thereof
WO2021228216A1 (zh) 可用作RORγ调节剂的联芳基类化合物
EP3150598B1 (en) Substituted tropane derivatives
WO2025176107A1 (zh) 一种吡啶酮衍生物及其在医药上的应用
WO2025067360A1 (zh) 一种DGKzeta拮抗剂及其在医药上的应用
WO2025247067A1 (zh) Kif18A抑制剂
TW202540093A (zh) Hpk1降解劑及其在醫藥上的應用
WO2025082464A1 (zh) 一种降解irak4的蛋白降解靶向嵌合体化合物及其应用

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20191107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20191107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200323

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20201106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210318

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210412

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210512

R150 Certificate of patent or registration of utility model

Ref document number: 6884800

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250